Covariate selection in high-dimensional propensity score analyses of treatment effects in small samples

American Journal of Epidemiology

Volumn 173, Issue 12, 2011, Pages 1404-1413

  Rassen, Jeremy A ^a   Glynn, Robert J ^a   Brookhart, M Alan ^b   Schneeweiss, Sebastian ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b IL   (United States)

Author keywords

algorithms; comparative effectiveness research; computing methodologies; confounding factors (epidemiology); epidemiologic methods; pharmacoepidemiology; propensity score

Indexed keywords

ANTIGLAUCOMA AGENT; CYCLOOXYGENASE 2 INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT;

ALGORITHM; COHORT ANALYSIS; COMPARATIVE STUDY; COVARIANCE ANALYSIS; DATA SET; DATABASE; EPIDEMIOLOGY; ERROR CORRECTION; RESEARCH WORK; SAMPLING; SENSITIVITY ANALYSIS; SPATIOTEMPORAL ANALYSIS;

AGED; ALGORITHM; ARTICLE; CLINICAL RESEARCH; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HIGH DIMENSIONAL PROPENSITY SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PROPENSITY SCORE; SAMPLING; SENSITIVITY ANALYSIS; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ALGORITHMS; COHORT STUDIES; CONFOUNDING FACTORS (EPIDEMIOLOGY); FEMALE; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PHARMACOEPIDEMIOLOGY; PREDICTIVE VALUE OF TESTS; PROPENSITY SCORE; SAMPLE SIZE;

NORTH AMERICA;

EID: 79958845225     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwr001     Document Type: Article

References (45)

1. McMahon AD. Approaches to combat with confounding by indication in observational studies of intended drug effects. Pharmacoepidemiol Drug Saf. 2003;12(7):551-558. (Pubitemid 37220641)
2. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol. 2005;58(4):323-337. (Pubitemid 40601980)
3. Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf. 2006; 15(5):291-303. (Pubitemid 43797117)
4. McCandless LC, Gustafson P, Levy AR. A sensitivity analysis using information about measured confounders yielded improved uncertainty assessments for unmeasured confounding. J Clin Epidemiol. 2008;61(3):247-255.
5. Schneeweiss S, Glynn RJ, Tsai EH, et al. Adjusting for unmeasured confounders in pharmacoepidemiologic claims data using external information: the example of COX2 inhibitors and myocardial infarction. Epidemiology. 2005;16(1):17-24. (Pubitemid 40239274)
6. Arah OA, Chiba Y, Greenland S. Bias formulas for external adjustment and sensitivity analysis of unmeasured confounders. Ann Epidemiol. 2008;18(8):637-646. (Pubitemid 352001388)
7. Rassen JA, Brookhart MA, Glynn RJ, et al. Instrumental variables I: instrumental variables exploit natural variation in nonexperimental data to estimate causal relationships. J Clin Epidemiol. 2009;62(12):1226-1232.
8. Greenland S. An introduction to instrumental variables for epidemiologists. Int J Epidemiol. 2000;29(4):722-729. (Pubitemid 30612241)
9. Brookhart MA, Wang PS, Solomon DH, et al. Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable. Epidemiology. 2006; 17(3):268-275.
10. Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol. 1991;133(2):144-153.
11. Schneeweiss S, Rassen JA, Glynn RJ, et al. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology. 2009;20(4): 512-522.
12. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41-55.
13. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997;127(8 pt 2):757-763. (Pubitemid 27446562)
14. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000;343(21):1520-1528.
15. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000;284(10):1247-1255.
16. Shepherd J, Blauw GJ, Murphy MB, et al. The design of a PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk. Am J Cardiol. 1999;84(10): 1192-1197. (Pubitemid 29507501)
17. Simes J, Furberg CD, Braunwald E, et al. Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling Project. Eur Heart J. 2002; 23(3):207-215. (Pubitemid 36358242)
18. Miettinen TA, Pyörälä K, Olsson AG, et al. Cholesterollowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation. 1997;96(12):4211-4218. (Pubitemid 28007446)
19. Schneeweiss S, Solomon DH, Wang PS, et al. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis. Arthritis Rheum. 2006;54(11): 3390-3398. (Pubitemid 44737149)
20. Solomon DH, Rassen JA, Glynn RJ, et al. The comparative safety of analgesics in older adults with arthritis. Arch Intern Med. 2010;170(22):1968- 1976.
21. Schneeweiss S, Patrick AR, Solomon DH, et al. Variation in the risk of suicide attempts and completed suicides by antidepressant agent in adults: a propensity score-adjusted analysis of 9 years' data. Arch Gen Psychiatry. 2010;67(5):497-506.
22. Schneeweiss S, Patrick AR, Solomon DH, et al. Comparative safety of antidepressant agents for children and adolescents regarding suicidal acts. Pediatrics. 2010;125(5):876-888.
23. Gail MH, Wieand S, Piantadosi S. Biased estimates of treatment effect in randomized experiments with nonlinear regressions and omitted covariate. Biometrika. 1984;71(3): 431-444.
24. Brookhart MA, Schneeweiss S, Rothman KJ, et al. Variable selection for propensity score models. Am J Epidemiol. 2006;163(12):1149-1156. (Pubitemid 43987579)
25. Bross ID. Spurious effects from an extraneous variable. J Chronic Dis. 1966;19(6):637-647.
26. Glynn RJ, Knight EL, Levin R, et al. Paradoxical relations of drug treatment with mortality in older persons. Epidemiology. 2001;12(6):682-689. (Pubitemid 33134531)
27. Glynn RJ, Schneeweiss S, Wang PS, et al. Selective prescribing led to overestimation of the benefits of lipid-lowering drugs. J Clin Epidemiol. 2006;59(8):819-828. (Pubitemid 44040877)
28. Redelmeier DA, Tan SH, Booth GL. The treatment of unrelated disorders in patients with chronic medical diseases. N Engl J Med. 1998;338(21):1516-1520. (Pubitemid 28226280)
29. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158(9): 915-920. (Pubitemid 37323253)
30. Weinberg CR. Toward a clearer definition of confounding. Am J Epidemiol. 1993;137(1):1-8. (Pubitemid 23077302)
31. Greenland S, Pearl J, Robins JM. Causal diagrams for epidemiologic research. Epidemiology. 1999;10(1):37-48. (Pubitemid 29014427)
32. Schneeweiss S. A basic study design for expedited safety signal evaluation based on electronic healthcare data. Pharmacoepidemiol Drug Saf. 2010;19(8):858-868.
33. Rothman KJ, Greenland S, Lash TL. Modern epidemiology. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008.
34. Peduzzi P, Concato J, Kemper E, et al. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol. 1996;49(12):1373-1379. (Pubitemid 27028925)
35. Seeger JD, Williams PL, Walker AM. An application of propensity score matching using claims data. Pharmacoepidemiol Drug Saf. 2005;14(7):465-476. (Pubitemid 40990742)
36. McAfee AT, Ming EE, Seeger JD, et al. The comparative safety of rosuvastatin: a retrospective matched cohort study in over 48,000 initiators of statin therapy. Pharmacoepidemiol Drug Saf. 2006;15(7):444-453. (Pubitemid 44150867)
37. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med. 2004;23(9):1351-1375. (Pubitemid 38594143)
38. Greenland S, Schwartzbaum JA, Finkle WD. Problems due to small samples and sparse data in conditional logistic regression analysis. Am J Epidemiol. 2000;151(5):531-539. (Pubitemid 30471029)
39. Stürmer T, Schneeweiss S, Brookhart MA, et al. Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores: nonsteroidal antiinflammatory drugs and short-term mortality in the elderly. Am J Epidemiol. 2005;161(9):891-898. (Pubitemid 40577844)
40. Austin PC. Some methods of propensity-score matching had superior performance to others: results of an empirical investigation and Monte Carlo simulations. Biom J. 2009; 51(1):171-184.
41. Judkins DR, Morganstein D, Zador P, et al. Variable selection and raking in propensity scoring. Stat Med. 2007;26(5): 1022-1033. (Pubitemid 46291129)
42. Brookhart MA, Stürmer T, Glynn RJ, et al. Confounding control in healthcare database research: challenges and potential approaches. Med Care. 2010;48(suppl 6):S114-S120.
43. Bhattacharya J, Vogt WB. Do Instrumental Variables Belong in Propensity Score Models? Cambridge, MA: The National Bureau of Economics Research; 2007.
44. Greenland S. Quantifying biases in causal models: classical confounding vs collider-stratification bias. Epidemiology. 2003;14(3):300-306. (Pubitemid 40417081)
45. Liu W, Brookhart MA, Setoguchi S. Impact of colliderstratification bias (M-bias) in pharmacoepidemiologic studies: a simulation study [abstract]. Pharmacoepidemiol Drug Saf. 2010;19(suppl 1):S212.